TCM
KPTI icon

Teza Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Teza Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-879
Closed -$169K – 204
2017
Q1 		$169K Buy
+879
New +$141K 0.05% 441

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Teza Capital Management's KPTI Position: Q2 2017 in Review

Teza Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2017, closing a stake of 879 shares — an estimated $169K sold.

Teza Capital Management first reported a position in KPTI in Q1 2017 and held it in 1 quarter. The position peaked at $169K in Q1 2017. 73 funds tracked by Wall St. Rank hold KPTI as of Q2 2017.

  • Teza Capital Management reported no remaining Karyopharm Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Teza Capital Management sold 879 Karyopharm Therapeutics shares in Q2 2017, an estimated $169K.
  • Teza Capital Management first reported a position in Karyopharm Therapeutics in Q1 2017 and held it in 1 quarter.
  • Teza Capital Management's Karyopharm Therapeutics position peaked at $169K in Q1 2017.
  • 73 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2017.

Based on Teza Capital Management's 13F filing for Q2 2017.